FDA label
What is paricalcitol used for?
The FDA-approved uses of paricalcitol, quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for paricalcitol (capsule) lists 2 uses: Chronic Kidney Disease Stages 3 and 4; Chronic Kidney Disease Stage 5.
Run it in Rivvi
Which 2027 plans near you dropped or restricted paricalcitol?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Paricalcitol, capsule, liquid filled
Indications and Usage, quoted from the label by TIME CAP LABORATORIES, INC (ANDA204948). Cross-references to other label sections are left out.
1.1 Chronic Kidney Disease Stages 3 and 4
Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4.
Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
1.2 Chronic Kidney Disease Stage 5 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD).
Source: DailyMed label, set id f593b575-7537-4531-87fc-c1b0814fd018, version 5, effective December 2, 2022. NDC 49483-687, one of 12 listings for this product.
Paricalcitol, capsule
Indications and Usage, quoted from the label by Bionpharma Inc. (ANDA202539). Cross-references to other label sections are left out.
Chronic Kidney Disease Stages 3 and 4
Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4.
Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Chronic Kidney Disease Stage 5
Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD).
Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Source: DailyMed label, set id 755476e5-62a2-4f01-92a3-307e192ad42c, version 5, effective December 27, 2023. NDC 69452-145, one of 10 listings for this product.
Paricalcitol, injection
Indications and Usage, quoted from the label by Eugia US LLC (ANDA205982). Cross-references to other label sections are left out.
Paricalcitol injection is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis.
Source: DailyMed label, set id 6937c596-9ca4-480e-9090-b9d8a3c271c8, version 8, effective October 23, 2025. NDC 55150-212, one of 8 listings for this product.
Questions
What is paricalcitol used for?
The FDA label for paricalcitol (capsule) lists 2 uses: Chronic Kidney Disease Stages 3 and 4; Chronic Kidney Disease Stage 5.
What drug class is paricalcitol?
FDA lists paricalcitol in the Vitamin D2 Analog and Vitamin D Analog established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.